Blood Res (2024) 59:11
Published online March 6, 2024
https://doi.org/10.1007/s44313-024-00010-0
© The Korean Society of Hematology
Correspondence to : *Young‑Uk Cho
yucho@amc.seoul.kr
© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Next-generation sequencing (NGS) allows high-throughput detection of molecular changes in tumors. Over the past 15 years, NGS has rapidly evolved from a promising research tool to a core component of the clinical laboratory. Sequencing of tumor cells provides an important step in detecting somatic driver mutations that not only characterize the disease but also influence treatment decisions. For patients with hematologic malignancies, NGS has been used for accurate classification and diagnosis based on genetic alterations. The recently revised World Health Organization classification and the European LeukemiaNet recommendations for acute myeloid leukemia consider genetic abnormalities as a top priority for diagnosis, prognostication, monitoring of measurable residual disease, and treatment choice. This review aims to present the role and utility of various NGS approaches for the diagnosis, treatment, and follow-up of hemato-oncology patients.
Keywords Next-generation sequencing, Leukemia, Diagnosis, Prognosis, Monitoring
Blood Res 2024; 59():
Published online March 6, 2024 https://doi.org/10.1007/s44313-024-00010-0
Copyright © The Korean Society of Hematology.
1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic‑Ro 43‑Gil, Songpa‑Gu, Seoul 05505, Korea
Correspondence to:*Young‑Uk Cho
yucho@amc.seoul.kr
© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Next-generation sequencing (NGS) allows high-throughput detection of molecular changes in tumors. Over the past 15 years, NGS has rapidly evolved from a promising research tool to a core component of the clinical laboratory. Sequencing of tumor cells provides an important step in detecting somatic driver mutations that not only characterize the disease but also influence treatment decisions. For patients with hematologic malignancies, NGS has been used for accurate classification and diagnosis based on genetic alterations. The recently revised World Health Organization classification and the European LeukemiaNet recommendations for acute myeloid leukemia consider genetic abnormalities as a top priority for diagnosis, prognostication, monitoring of measurable residual disease, and treatment choice. This review aims to present the role and utility of various NGS approaches for the diagnosis, treatment, and follow-up of hemato-oncology patients.
Keywords: Next-generation sequencing, Leukemia, Diagnosis, Prognosis, Monitoring
Table 1 . Genetic variants detectable by next-generation sequencing assay and of clinical utility in hematologic malignancies.
Diseases | Mutated genes | Fusions |
---|---|---|
Myeloid malignancies | ABL1, ANKRD26, ASXL1a,b, BCORa,b, BCORL1a, BRCC3a, CALRc, CBLa, CEBPAc, CTCFa, DDX41c, DNMT3Aa, ETNK1, ETV6c, EZH2b,c, FLT3c,d, GNASa, GNB1a, IDH1a,c, IDH2a,c, JAK2a,c, KITc, KMT2Ad, KRASa,c, MPLc, NPM1c, NRASa,c, PPM1Da, PTPN11a,c, RAD21c, RUNX1c, SETBP1a, SF3B1a,b,c, SH2B3, SRSF2a,b,c, STAG2b,c, TET2a, TP53a,c, U2AF1a,b,c, WT1c, ZBTB33a, ZRSR2b | BCR::ABL1, CBFB::MYH11, DEK::NUP214, KMT2Ar, MECOMr, NUP98r, PML::RARA, RBM15::MRTFA, RUNX1::RUNX1T1, |
Lymphoid malignanciese | BRAF, CXCR4, CYLD, DIS3, EGR1, FAM46C, FGFR3, HIST1H1E, ID3, IRF4, KRAS, LTB, MAX, MYD88, NRAS, PAX5, RB1, STAT3, STAT5B, TCF3, TP53, TRAF3 | ABL1rf, ABL2rf, BCR::ABL1, CRLF2rf, CSF1Rrf, DGKHrf, DUX4r, EPORrf, ETV6::RUNX1, IGH::IL3, other IGHr, IL2RBrf, JAK2rf, KMT2Ar, MEF2Dr, MYCr, NTRK3rf, NUTM1r, PAX5r, PGDFRBrf, PTK2Brf, TCF3::PBX1, TCF3::HLF, TSLPrf, TYK2rf, ZNF384r |
All genes are listed alphabetically.
a Genes commonly mutated in clonal hematopoiesis [1].
b Presence of mutations in these genes defines the category ‘acute myeloid leukemia myelodysplasia-related’ according to the WHO 2022 classification [1].
c Basic set of genes provided by the ELN guideline may be useful in a panel approach for measurable residual disease monitoring in acute myeloid leukemia [18].
d Reliable detection of FLT3-internal tandem duplication or KMT2A-partial tandem duplication using targeted NGS assay may require specialized bioinformatics analysis.
e Only genetic aberrations in blood- or bone marrow-derived lymphoid malignancies were considered.
f These genes are typically involved in gene fusions that characterize BCR::ABL1-like features.
Mi‑Ae Jang
Blood Res 2024; 59():Hyewon Lee
Blood Res 2023; 58(S1): S66-S82Sung-Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joon Ho Moon, Chang-Ki Min, Dok Hyun Yoon, Sung-Soo Yoon, Je-Jung Lee, Chae Moon Hong, Ka-Won Kang, Jihyun Kwon, Kyoung Ha Kim, Dae Sik Kim, Sung Yong Kim, Sung-Hyun Kim, Yu Ri Kim, Young Rok Do, Yeung-Chul Mun, Sung-Soo Park, Young Hoon Park, Ho Jin Shin, Hyeon-Seok Eom, Sang Eun Yoon, Sang Mee Hwang, Won Sik Lee, Myung-won Lee, Jun Ho Yi, Ji Yun Lee, Ji Hyun Lee, Ho Sup Lee, Sung-Nam Lim, Jihyang Lim, Ho-Young Yhim, Yoon Hwan Chang, Jae-Cheol Jo, Jinhyun Cho, Hyungwoo Cho, Yoon Seok Choi, Hee jeong Cho, Ari Ahn, Jong Han Choi, Hyun Jung Kim and Kihyun Kim
Blood Res 2025; 60():